Related Experiment Videos
The pathological consequences of anaemia.
D S Silverberg1, A Iaina, D Wexler
1Department of Nephrology, Tel Aviv Medical Center, Tel Aviv, Israel.
Clinical and Laboratory Haematology
|June 26, 2001
Summary
Anemia of chronic disease, common in conditions like heart failure, is caused by inflammation. Treating it with erythropoietin (EPO) and iron improves patient well-being and reduces hospitalizations.
Area of Science:
- Internal Medicine
- Nephrology
- Cardiology
- Rheumatology
Background:
- Anemia is prevalent in patients with chronic diseases, including chronic renal failure, inflammatory bowel disease, rheumatoid arthritis, and congestive heart failure (CHF).
- This anemia, often termed anemia of chronic disease, is partly attributed to elevated cytokines and leukotrienes.
- These inflammatory mediators disrupt erythropoietin (EPO) efficacy in the bone marrow and impair iron release from the reticuloendothelial system.
Purpose of the Study:
- To highlight the significant impact of anemia in chronic disease patients.
- To discuss the therapeutic benefits of treating anemia with subcutaneous EPO and intravenous (IV) iron.
- To emphasize the underdiagnosis and undertreatment of this condition.
Main Methods:
- The abstract discusses the established pathophysiology of anemia in chronic diseases.
- It reviews the clinical outcomes associated with treating this anemia using subcutaneous erythropoietin (EPO) and intravenous (IV) iron.
- The review implicitly compares the benefits of treatment against the consequences of untreated anemia.
Main Results:
- Treatment with subcutaneous EPO and IV iron significantly improves various patient symptoms, including weakness, fatigue, cachexia, nutritional status, mood, and cognitive function.
- In congestive heart failure (CHF) patients, this treatment also enhances cardiac function, improves functional class, preserves renal function, and substantially reduces hospitalizations.
- The therapeutic interventions demonstrate rapid and widespread improvements across multiple patient health aspects.
Conclusions:
- Anemia associated with chronic diseases is a treatable condition with substantial benefits.
- Subcutaneous EPO and IV iron are effective in improving quality of life and clinical outcomes in affected patients.
- There is a critical need to address the frequent neglect and undertreatment of anemia in chronic disease populations.